Generic name (INN) |
Physicochemistry[44] |
Mechanism of action[45] |
Routes of administration [45][46][47] |
Pharmacokinetics[44] |
Indications [45][46][47] |
Major safety concerns [45][46][47] |
Nonsteroidal anti-inflammatory drugs |
Unselective agents |
Aceclofenac | Comes in betadex salt and free acid forms; practically insoluble in water, soluble in many organic solvents; degrades on contact with light; phenylacetic acid derivative. | As per diclofenac. | Oral (PO.) | Protein binding > 99%; half-life = 4 hours; metabolised to diclofenac (minor); excretion = urine (67%). | As per diclofenac. | As per diclofenac. |
Acemetacin | Comes in free form; practically insoluble in water, soluble in certain organic solvents; degrades upon contact with light. Chemically related to indometacin | As per diclofenac. | PO. | Slightly metabolised to indometacin. | Rheumatoid arthritis, osteoarthritis and lower back pain. | As per diclofenac. |
Amfenac | No available data. | As per diclofenac. | PO. | No data. | Pain and inflammation. | As diclofenac. |
Aminophenazone | Related to phenylbutazone. | As per diclofenac. | PO. | Not available. | Musculoskeletal and joint disorders. | Agranulocytosis and cancer. |
Ampiroxicam | Related to piroxicam. | As per diclofenac. | PO. | No data. | Rheumatoid arthritis and osteoarthritis. | Photosensitivity and other AEs typical of NSAIDs. |
Amtolmetin guacil | Prodrug to tolmetin. | As per diclofenac. | PO. | No data. | As per diclofenac. | As per diclofenac. |
Aspirin | Comes in free form, aluminium and lysine salt forms; fairly insoluble in water (1 in 300); highly soluble (1 in 5) in alcohol; degrades on contact with air. Salicylate. | Irreversibly inhibits COX-1 and COX-2; hence inhibiting prostaglandin synthesis. | PO, IM, IV, rectal | Bioavailability = 80–100%; protein binding = 25–95% (inversely dependent on plasma concentration); half life = 2–3 hours, 15–30 hours (higher doses); excretion = 80–100%.[48] | Blood thinning; mild-to-moderate pain; fever; rheumatic fever; migraine; rheumatoid arthritis; Kawasaki's disease | GI bleeds; ulcers; Reye syndrome; nephrotoxicity; blood dyscrasias (rarely); Stevens–Johnson syndrome (uncommon/rare) |
Azapropazone | Comes in free form; fairly insoluble in water and chloroform, soluble in ethanol; phenylbutazone. | As per diclofenac. | PO, rectal. | No data available. | Rheumatoid arthritis; gout; ankylosing spondylitis. | As per diclofenac. |
Bendazac | Comes in free acid and lysine salt forms. Chemically related to indometacin. | As per acetametacin. | Topical, ophthalmologic. | N/A | Skin conditions (such as contact dermatitis) and cataracts. | Hepatotoxicity reported. |
Benorilate | Aspirin-paracetamol ester. Practically insoluble in water, sparingly soluble in ethanol and methanol, soluble in acetone and chloroform. | As per aspirin and paracetamol. | PO. | Unavailable. | Osteoarthritis; rheumatoid arthritis; soft-tissue rheumatism; mild-moderate pain and fever. | As per aspirin and paracetamol. |
Benzydamine | Comes in free acid form; freely soluble in water. | As per diclofenac. | Topical, PO, rectal, spray and vaginal. | No data available. | Musculoskeletal disorders; soft-tissue disorders; sore throat. | As per diclofenac. |
Bromfenac | Comes in free acid form; phenylacetic acid derivative. | Reversible COX-1/COX-2 inhibitor. | Ophthalmologic. | N/A | Postoperative pain and inflammation. | Corneal ulceration. |
Bufexamac | Comes in free acid form; practically insoluble in water, soluble in a few organic solvents; degrades upon contact with light. | Reversible COX-1/COX-2 inhibition. | Topical. | No data. | Skin disorders. | Skin conditions, such as contact dermatitis. |
Carbasalate | Comes in calcium salt form; fairly soluble in water. | Is metabolised to aspirin and urea. As per aspirin. | Oral. | No data. | Used for thromboembolic disorders. | As per diclofenac. |
Clonixin | Comes in free acid and lysine salt forms. | Reversible COX-1/COX-2 inhibition. | PO, IM, IV, rectal. | No data. | Pain. | As per diclofenac. |
Dexibuprofen | D-isomer of ibuprofen. Propionic acid derivative. | As per diclofenac. | PO. | Bioavailability = ?; protein binding = 99%; metabolism = hepatic via carboxylation and hydroxylation; half-life = 1.8–3.5 hours; excretion = Urine (90%).[49] | Osteoarthritis; mild-moderate pain and menstrual pain.[50] | As per diclofenac. |
Diclofenac | Comes in sodium, potassium and diethylamine (topically used as a gel) salt forms; sparingly soluble in water but soluble in ethanol. Unstable in the presence of light and air. Indole acetic acid derivative. | Reversible COX-1/COX-2 inhibitor. | PO and topical. | Bioavailability = 50–60%; protein binding = 99–99.8%; hepatic metabolism; half-life = 1.2–2 hours; excretion = urine (50–70%), faeces (30–35%) | Rheumatoid arthritis; osteoarthritis; inflammatory pain (e.g. period pain); local pain/inflammation (as a gel); actinic keratoses; heavy menstrual bleeding | As per aspirin, except without Reye syndrome and with the following additions: myocardial infarctions, strokes and hypertension. More prone to causing these AEs compared to the other non-selective NSAIDs.[51] |
Diethylamine salicylate | Freely soluble in water; degrades upon contact with light and iron. | As per diclofenac. | Topical. | N/A. | Rheumatic and musculoskeletal pain. | As per bufexamac. |
Diflunisal | Comes in free acid and arginine salt forms; practically insoluble in water, soluble in ethanol; degrades upon contact with light. | As per diclofenac. | PO, IM, IV. | Bioavailability = 80–100%; protein binding > 99%; volume of distribution = 0.11 L/kg; hepatic metabolism; half-life = 8–12 hours; excretion = urine (90%), faeces (<5%).[44][52] | Pain; osteoarthritis; rheumatoid arthritis. | As per diclofenac. |
Epirizole | Comes in free form. | As per diclofenac. | PO. | Not available. | Rheumatoid arthritis. | As per diclofenac. |
Ethenzamide | Comes in free form; salicylate. | As per diclofenac. | PO. | Not available. | Musculoskeletal pain; fever. | As per diclofenac. |
Etofenamate | Liquid; practically insoluble in water, miscible with ethyl acetate and methanol. | As per diclofenac. | Topical. | Not available. | Musculoskeletal, joint and soft-tissue disorders. | As per bufexamac. |
Felbinac | Comes in free and diisopropanolamine salt forms; practically insoluble in water and ethanol, soluble in methanol. | As per diclofenac. | Topical. | N/A | Musculoskeletal pain and soft tissue injuries. | As per bufexamac. |
Fenbufen | Comes as free acid; fairly insoluble in most solvents (including water); propionic acid derivative. | As per diclofenac. | PO. | Protein binding > 99%; half-life = 10–17 hours. | As per diclofenac. | As per diclofenac. |
Fenoprofen | Comes in calcium salt; fairly insoluble in water and chloroform and fairly soluble in alcohol; sensitive to degradation by air. Propionic acid derivative. | As per diclofenac. | PO. | Bioavailability = ?; protein binding = 99%; hepatic metabolism; excretion = urine, faeces.[53] | Pain; rheumatoid arthritis and osteoarthritis. | As per diclofenac. |
Fentiazac | Comes in free form and calcium salt; acetic acid derivative. | As per diclofenac. | PO. | No data. | As per diclofenac. | As per diclofenac. |
Fepradinol | Comes in free acid and hydrochloride salt forms. | As per diclofenac. | Topical. | N/A | Local inflammatory response. | As per bufexamac. |
Feprazone | Comes in free acid and piperazine salt forms. Phenylbutazone. | As per diclofenac. | PO, Rectal, topical. | Not available. | As per diclofenac. | As per bufexamac (topical use) and diclofenac (PO/rectal). |
Floctafenine | Comes in free acid form; anthranilic acid derivative. | As per diclofenac. | Oral. | Extensively metabolised by the liver; half-life = 8 hours; excretion = urinary and biliary. | Short-term relief from pain. | As per diclofenac. |
Flufenamic acid | Comes in free acid form and aluminium salt form; anthranilic acid. | As per diclofenac. | Topical. | N/A | Soft tissue inflammation and pain. | As per bufexamac. |
Flurbiprofen | Comes in sodium salt and free acid forms; fairly insoluble in water but soluble in ethanol; sensitive to degradation by air. Propionic acid derivative. | As per diclofenac. | PO, IM, IV, ophthalmologic. | Bioavailability = 96% (oral); protein binding > 99%; volume of distribution = 0.12 L/kg; excretion = urine (70%).[54] | Ophthalmologic: Vernal keratoconjunctivitis; postoperative ocular swelling; herpetic stromal keratitis, excimer laser photorefractive keratectomy; ocular gingivitis. Systemic use: rheumatoid arthritis; osteoarthritis.[54] | As per bromfenac (ophthalmologic) and diclofenac (PO/IM/IV). |
Glucametacin | Indometacin derivative. | As per diclofenac. | PO. | Not available. | Musculoskeletal, joint, peri-articular and soft-tissue disorders. | As per diclofenac. |
Ibuprofen | Comes in lysine salt, potassium salt and free acid forms; practically insoluble in water, but soluble in ethanol, acetone, methanol, dichloromethane and chloroform. Degrades in the presence of air. Propionic acid derivative. | As per diclofenac. | PO, IV, topical | Bioavailability = 80–100%; protein binding = 90–99%; hepatic metabolism, mostly via CYP2C9 and CYP2C19-mediated oxidation; excretion = Urine (50–60%), faeces.[55] | Pain; fever; inflammatory illness; rheumatoid arthritis; osteoarthritis; heavy menstrual bleeding; patent ductus arteriosus.[46][56][57] | As per diclofenac, except with lower risk of myocardial infarction, stroke and hypertension. |
Imidazole salicylate | Comes in free form. Salicylate. | As per diclofenac. | PO, rectal, topical. | Not available. | Muscular and rheumatic pain. | As per bufexamac (topical use) and diclofenac (PO/rectal). |
Indometacin | Comes in free acid and sodium salt forms; practically insoluble in water and most solvents; sensitive to degradation by light. Acetic acid derivative. | As per diclofenac. | PO, IV, rectal | Bioavailability = 100% (oral); protein binding = 90%; hepatic metabolism; excretion = urine (60%), faeces (33%).[58] | Rheumatoid arthritis; osteoarthritis; gout; ankylosing spondylitis; period pain; patent ductus arteriosus.[46] | As per diclofenac. |
Isonixin | Comes in free form. | As per diclofenac. | PO, rectal and topical. | Not available. | Musculoskeletal and joint disorders. | As per bufexamac (topical use) and diclofenac (PO/rectal). |
Kebuzone | Comes in free and sodium salt form; phenylbutazone derivative. | As per diclofenac. | IM, PO. | Not available. | As per diclofenac. | As per diclofenac. |
Ketoprofen | Comes in free acid, lysine salt, sodium salt and hydrochloride salt forms; the dex-enantiomer comes in trometamol salt form. Practically insoluble in water; freely soluble in most other solvents. Propionic acid derivative. | As per diclofenac. | PO, rectal, topical, transdermal, intravenous, intramuscular.[59][60] | Bioavailability > 92% (oral), 70–90% (rectal); protein binding > 99%; volume of distribution = 0.1–0.2 L/kg; hepatic metabolism; half-life = 1.5–2 hours (oral), 2.2 hours (rectal), 2 hours (intravenous).[61][62] | Rheumatoid arthritis, osteoarthritis and superficial sporting injuries (topical use).[46][63] | As per diclofenac. |
Ketorolac | Comes in the trometamol salt form; highly soluble in water. Degrades in the presence of light. Acetic acid derivative. | As per diclofenac. | PO, IM, IV, intranasal, tromethamine and ophthalmologic. | Bioavailability of IM formulation = 100%; protein binding = 99%; hepatic metabolism mostly via glucoronic acid conjugation and p-hydroxylation; half-life = 5–6 hours; excretion = urine (91.4%), faeces (6.1%).[64] | Mild-moderate postoperative pain; acute migraine; inflammation of the eye due to cataract surgery or allergic seasonal conjunctivitis; prevention of acute pseudophakic cystoid macular oedema.[65][66][67][68][69][70][71] | As per diclofenac. |
Lornoxicam | Hydrochloride salt form used; oxicam derivative. | As per diclofenac. | PO. | Protein binding = 99%; volume of distribution = 0.2 L/kg; half-life = 3–5 hours; excretion = faeces (51%), urine (42%).[72][73] | Acute and chronic pain. | As per diclofenac. |
Loxoprofen | Comes in sodium salt form. Propionic acid derivative. | As per diclofenac. | Topical. | N/A | Local inflammation and pain. | As per diclofenac. |
Magnesium salicylate | Comes in free form; soluble in water and ethanol; salicylate. | As per diclofenac. | PO. | Not available. | As per diclofenac. | As per diclofenac. |
Meclofenamic acid | Comes in free acid and sodium salt form, sodium salt is the form used in human medicine; practically insoluble in water (free acid) and freely soluble in water (sodium salt); sensitive to degradation by air and light. | As per diclofenac. | PO. | Protein binding > 99%; half-life = 2–4 hours; hepatically metabolised via oxidation, hydroxylation, dehalogenation and conjugation with glucuronic acid; excretion = urine, faeces (20–30%).[44] | Osteoarthritis; rheumatoid arthritis; mild-moderate pain; dysmenorrhoea; menorrhagia. | As per diclofenac. |
Mefenamic acid | Comes in free acid form; practically insoluble in water, fairly insoluble in organic solvents; degrades on contact with air and light. Anthranilic acid derivative. | As per diclofenac. | PO. | Protein binding extensive; hepatic metabolism, mostly via CYP2C9; half-life = 2 hours; excretion = urine (66%), faeces (20–25%).[74] | Inflammatory pain and heavy menstrual bleeding.[46] | As per diclofenac. |
Mofezolac | Comes in free form. | As per diclofenac. | PO. | Not available. | Musculoskeletal and joint pain. | As per diclofenac. |
Morniflumate | Comes in free acid form; niflumic acid derivative. | As per diclofenac. | PO, rectal. | Not available. | Inflammatory conditions. | As per diclofenac. |
Nabumetone | Comes in free acid form; practically insoluble in water, freely soluble in acetone; degrades on contact with air and light. | As per diclofenac. | PO. | Protein binding = 99%; hepatically metabolised; half-life = 24 hours; excretion = urine (80%), faeces (9%).[75] | Osteoarthritis; rheumatoid arthritis. | As per diclofenac. |
Naproxen | Comes in free acid and sodium form; practically insoluble in water in free form, freely soluble in water (sodium salt), fairly soluble in most organic solvents. Degrades on contact with air and light. Propionic acid derivative. | As per diclofenac. | PO. | Bioavailability = ?; protein binding > 99.5%; volume of distribution = 10% of bodyweight; half-life = 12–15 hours; excretion = urine (95%), faeces (<3%).[76] | Rheumatoid arthritis; osteoarthritis; ankylosing spondylitis; juvenile idiopathic arthritis; inflammatory pain; heavy menstrual bleeding. | As per diclofenac. less prone to causing thrombotic events compared to other non-selective NSAIDs.[51] |
Nepafenac | Comes in free form; related to amfenac. | As per diclofenac. | Ophthalmologic. | Unavailable. | Inflammation and pain following cataract surgery. | As per bromfenac. |
Niflumic acid | Comes in free acid form, glycinamide and ethyl ester form; practically insoluble in water, soluble in ethanol, acetone and methanol. Nicotinic acid derivative. | As per diclofenac. | PO, rectal (ethyl ester, morniflumate). | Unavailable. | Musculoskeletal, joint and mouth inflammatory disorders. | As per diclofenac. |
Oxaprozin | Comes in potassium and free acid forms; degrades upon contact with light. Propionic acid derivative. | As per diclofenac. | PO. | Bioavailability = ?; protein binding > 99.5%; volume of distribution = 0.15–0.25 L/kg; half-life = 50–60 hours; excretion = urine (65), faeces (35%).[77][78] | Osteoarthritis; rheumatoid arthritis. | As per diclofenac. |
Oxyphenbutazone | Comes in free form. Phenylbutazone. | As per diclofenac. | PO, Ophthalmologic. | Unavailable. | Ophthalmologic: Episcleritis. Systemic (now seldom used due to adverse effects): ankylosing spondylitis; rheumatoid arthritis; osteoarthritis. | As per bromfenac. For systemic use haematological side effects such as aplastic anaemia; agranulocytosis; leucopenia; neutropenia; etc. |
Phenazone | No data. | As per diclofenac. | PO, otolaryngologic. | Protein binding < 10%; half-life = 12 hours; hepatic metabolised; excretion = urine (primary), faeces. | Acute otitis media. | Nephrotoxicity and haematologic toxicity and other AEs typical of NSAIDs. |
Phenylbutazone | Comes in free form; practically insoluble in water, freely soluble in most organic solvents; degrades upon contact with light and air. | As per diclofenac. | PO, rectal, topical. | No data available. | Ankylosing spondylitis; acute gout; osteoarthritis; rheumatoid arthritis. | Haematologic toxicity (including agranulocytosis, aplastic anaemia) and AEs typical of NSAIDs. |
Piketoprofen | Comes in free form. | As per diclofenac. | Topical. | N/A. | Musculoskeletal, joint, peri-articular and soft-tissue disorders. | As per other topical NSAIDs. |
Piroxicam | Comes in free acid and betadex salt forms; practically insoluble in water, slightly soluble in ethanol; degrades on contact with air and light. Enolic acid derivative. | As per diclofenac. | PO, topical. | Protein binding = 99%; extensively hepatically metabolised; half-life = 36–45 hours; excretion = urine, faeces.[79][80] | Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and sports injuries (topical use).[46] | As per diclofenac. |
Proglumetacin | Comes in maleate salt form; indometacin derivative. | As per diclofenac. | PO, rectal, topical. | Not available. | Musculoskeletal and joint disorders. | As per diclofenac. |
Proquazone | Comes in free form. | As per diclofenac. | PO, rectal. | Not available. | As per diclofenac. | As per diclofenac. |
Pranoprofen | No data. | As per diclofenac. | PO, ophthalmologic. | Not available. | Pain, inflammation and fever. | As per diclofenac. |
Salamidacetic acid | Comes in sodium and diethylamine salt forms; salicylate. | As per diclofenac. | PO. | Unavailable. | Musculoskeletal disorders. | As per diclofenac. |
Salicylamide | Fairly insoluble in water and chloroform; soluble in most other organic solvents; salicylate. | As per diclofenac. | PO, topical. | No data. | Muscular and rheumatic diseases. | As per diclofenac. |
Salol | No data. | As per diclofenac. | PO, topical. | No data. | Lower urinary tract infections. | As per diclofenac. |
Salsalate | Degrades upon contact with air; salicylate derivative. | As per diclofenac. | PO. | Hepatic metabolism; half-life = 7–8 hours; excretion = urine.[81] | Rheumatoid arthritis, osteoarthritis. | As per diclofenac. |
Sodium salicylate | Freely soluble in water; degrades upon contact with air and light; salicylate. | As per diclofenac. | PO, IV, topical. | No data. | Pain, fever and rheumatic conditions. | Cardiac problems; otherwise As per diclofenac. |
Sulindac | Comes in free acid and sodium salt forms; practically insoluble in water and hexane, very slightly soluble in most organic solvents. Degrades upon contact with light. Acetic acid derivative. | As per diclofenac. | PO, rectal. | Bioavailability = 90%; protein binding = 93% (sulindac), 98% (active metabolite); hepatic metabolism; excretion = urine (50%), faeces (25%).[82] | Rheumatoid arthritis; osteoarthritis; gout; ankylosing spondylitis; inflammatory pain.[46] | As per diclofenac. |
Suxibuzone | Practically insoluble in water, soluble in ethanol and acetone; phenylbutazone. | As per diclofenac. | PO, topical. | No data. | Musculoskeletal and joint disorders. | As per phenylbutazone. |
Tenoxicam | Comes as free acid; practically insoluble in water, fairly insoluble in organic solvents; degrades upon contact with light. | As per diclofenac. | PO, rectal. | Bioavailability = 100% (oral), 80% (rectal); protein binding = 99%; volume of distribution = 0.15 L/kg; half-life = 60–75 hours; excretion = urine (67%), faeces (33%).[83] | Osteoarthritis; rheumatoid arthritis; soft tissue injury. | As per diclofenac. |
Tetridamine | No data. | As per diclofenac. | Vaginal. | No data. | Vaginitis. | As per diclofenac. |
Tiaprofenic acid | Comes as free acid; practically insoluble in water but freely soluble in most organic solvents; propionic acid derivative; degrades upon contact with light. Propionic acid derivative. | As per diclofenac. | PO. | Protein binding > 99%; volume of distribution = 0.1–0.2 L/kg; hepatic metabolism; half-life = 2–4 hours.[84] | Ankylosing spondylitis; osteoarthritis; rheumatoid arthritis; fibrosis; capsulitis; soft-tissue disorders. | As per diclofenac. |
Tiaramide | No data. | As per diclofenac. | PO. | No data. | Pain; inflammation. | As per diclofenac. |
Tinoridine | No data. | As per diclofenac. | No data. | No data. | Pain; inflammation. | As per diclofenac. |
Tolfenamic acid | Comes as free acid; practically insoluble in water; degrades upon contact with light; anthranilic acid. | As per diclofenac. | PO. | Protein binding = 99%; half-life = 2 hours; hepatically metabolised; excretion = urine (90%), faeces. | Migraine; osteoarthritis; rheumatoid arthritis; dysmenorrhoea. | As per diclofenac. |
Tolmetin | Comes in sodium salt form; freely soluble in water, slightly soluble in ethanol, freely soluble in methanol. Acetic acid derivative. | As per diclofenac. | PO. | Protein binding > 99%; volume of distribution = 7–10 L; half-life = 1 hour; excretion = urine (90%).[85] | Osteoarthritis; rheumatoid arthritis. | As per diclofenac. |
Ufenamate | No data. | No data. | Topical. | No data. | Inflammatory skin disorders. | As per other topical NSAIDs. |
COX-2 selective inhibitors |
Celecoxib | Comes in free form; practically insoluble in water, fairly soluble in organic solvents. Degrades on contact with light and moisture. Sulfonamide. | Selective COX-2 inhibitor. | PO. | Protein binding = 97%; hepatic metabolism, mostly via CYP2C9; faeces (57%), urine (27%).[86] | Rheumatoid arthritis; osteoarthritis; ankylosing spondylitis; pain due to dysmenorrhoea or injury. | As per non-selective NSAIDs. More prone to causing thrombotic events than most of them, however, except diclofenac. |
Etodolac | Comes in free form; practically insoluble in water, freely soluble in acetone and dehydrated alcohol. Acetic acid derivative. | As per celecoxib. | PO. | Bioavailability = ?; protein binding > 99%; volume of distribution = 0.41 L/kg; half-life = 6–7 hours; excretion = urine (73%).[87][88][89] | Rheumatoid arthritis, including juvenile idiopathic arthritis; osteoarthritis; acute pain. | As per diclofenac. |
Etoricoxib | Comes in free form; sulfonamide. | As per celecoxib. | PO. | Bioavailability = 100%; protein binding = 91.4%; volume of distribution = 120 L; half-life = 22 hours; hepatic metabolism; excretion = urine (70%), faeces (20%).[90] | Acute pain; gout; osteoarthritis. | As per diclofenac. |
Lumiracoxib† | Comes in free form; acetic acid derivative. | As per celecoxib. | PO. | Bioavailability = 74%; protein binding > 98%; extensive hepatic metabolism, mostly via CYP2C9; half-life = 3–6 hours; excretion = Urine (50%), faeces (50%).[91] | Osteoarthritis. | As above, plus hepatotoxicity. |
Meloxicam | Comes in free form; fairly insoluble in water and in most organic solvents; oxicam derivative. | As per celecoxib. | PO, rectal. | Bioavailability = 89%; protein binding > 99%; volume of distribution = 0.1–0.2 L/kg; half-life = 22–24 hours; extensive hepatic metabolism; excretion = urine (45%), faeces (47%).[92] | Osteoarthritis; rheumatoid arthritis. | As per diclofenac. |
Nimesulide | Comes in free and betadex form; practically insoluble in water and ethanol, soluble in acetone. | As per celecoxib. | PO, rectal, topical. | Unavailable. | Acute pain; dysmenorrhoea; sprains (topical); tendinitis. | As per diclofenac. |
Parecoxib | Comes in sodium salt form; sulfonamide. | As per celecoxib. | IM, IV. | Plasma binding = 98%; volume of distribution = 55 L; hepatic metabolism, mostly via CYP2C9, CYP3A4; half-life = 8 hours; excretion = urine (70%).[93] | Postoperative pain. | As per diclofenac. |
Rofecoxib† | Comes in free form; sulfonamide. | As per celecoxib. | PO. | Bioavailability = 93%; protein binding = 87%; hepatic metabolism; half-life = 17 hours.[94][95] | Acute pain; osteoarthritis; rheumatoid arthritis. | As per diclofenac. |
Valdecoxib† | Comes in free form; sulfonamide. | As per celecoxib. | PO. | Bioavailability = 83%; protein binding = 98%; hepatic metabolism, mostly via CYP3A4 and CYP2C9; half-life = 8.11 hours; excretion = urine (90%).[96] | Pain from dysmenorrhoea; rheumatoid arthritis; osteoarthritis. | As above and also potentially fatal skin reactions (e.g. toxic epidermal necrolysis). |
Opioids |
Those with a morphine skeleton |
Buprenorphine | Comes in free and hydrochloride salt forms; fairly insoluble in water, soluble in ethanol, methanol and acetone; degrades upon contact with light. | Partial agonist at the mu opioid receptor; agonist at delta opioid receptor; antagonist at kappa opioid receptor. | Sublingual, transdermal, IM, IV, intranasal, epidural, SC. | Bioavailability = 79% (sublingual); protein binding = 96%: volume of distribution = 97–187 L/kg; half-life = 20–36 hours; excretion = urine, faeces.[97] | Opioid dependence, moderate-severe pain. | As per codeine, respiratory effects are subject to a ceiling effect. |
Codeine | Comes in free form, hydrochloride salt, sulfate salt and phosphate salts; soluble in boiling water (free form), freely soluble in ethanol (free form), soluble/freely soluble in water (salt forms); sensitive to degradation by light. Methoxy analogue of morphine. | Metabolised to morphine, which activates the opioid receptors. | PO, IM, IV. | Extensive hepatic metabolism, mostly via CYP2D6, to morphine; half-life = 3–4 hours; excretion = urine (86%).[98] | Mild-moderate pain, often in combination with paracetamol or ibuprofen. | Constipation, dependence, sedation, itching, nausea, vomiting and respiratory depression. |
Diamorphine | Comes in hydrochloride salt form; freely soluble in water, soluble in alcohol; degrades upon contact with light. Diacetyl derivative of morphine. | Rapidly hydrolysed to 6-acetylmorphine and then to morphine after crossing the blood-brain barrier which in turn activates the opioid receptors in the CNS. | IM, intrathecal, intranasal, PO, IV, SC. | Extensively metabolised to morphine with 6-acetylmorphine as a possible intermediate. Mostly excreted in urine. | Severe pain (including labour pain); cough due to terminal lung cancer; angina; left ventricular failure. | As per codeine. Higher potential for abuse compared to other opioids due to its rapid penetration of the blood-brain barrier. |
Dihydrocodeine | Comes in freebase, hydrochloride, phosphate, polistirex, thiocyanate, tartrate, bitartrate and hydrogen tartrate salt forms; freely soluble in water, practically insoluble in organic solvents (hydrogen tartrate salt); degrades upon contact with air and light. | Opioid receptor agonist. | IM, IV, PO, SC. | Bioavailability = 20%; extensive hepatic metabolism, partly via CYP2D6 to dihydromorphine and CYP3A4 to nordihydrocodeine; half-life = 3.5 –5 hours; excretion = urine. | Moderate-severe pain; usually in combination with paracetamol and/or aspirin. | As per codeine. |
Ethylmorphine | Comes in freebase, hydrochloride, camphorate and camsilate salt forms; soluble in water and alcohol; degrades upon contact with light. | Opioid receptor ligand. | PO. | No data. | Cough suppressant. | As per codeine. |
Hydrocodone | Comes in hydrochloride/tartrate salt form; freely soluble in water, practically insoluble in most organic solvents; degrades upon contact with light/air. | Opioid receptor ligand. | PO. | Protein binding = 19%; extensively hepatically metabolised, mostly via CYP3A4, but via CYP2D6 to a lesser extent to hydromorphone; half-life = 8 hours; excretion = urine.[99] | Chronic pain. | As per codeine. |
Hydromorphone | Comes in hydrochloride salt form; freely soluble in water, fairly insoluble in organic solvents; degrades upon contact with light or temperatures outside 15 °C and 35 °C. | Opioid receptor agonist. | IM, IV, PO, SC. | Bioavailability = 50–62% (oral); protein binding = 8–19%; extensively hepatically metabolised; half-life = 2–3 hours; excretion = urine.[100] | Moderate-severe pain; cough. | As per codeine. |
Morphine | Comes in freebase form, hydrochloride salt, sulfate salt and tartrate salt forms; soluble in water; degrades in the presence of light. | Opioid receptor agonist (μ, δ, κ). | IM, intrathecal, PO, IV, SC, rectal. | Protein binding = 35%; extensive hepatic metabolism, with some metabolism occur in the gut after oral administration; half-life = 2 hours; excretion = urine (90%). | Moderate-severe pain. | As per codeine. |
Nicomorphine | Dinicotinic acid ester derivative of morphine. | As per morphine. | IM, IV, PO, rectal, SC. | No available data. | Moderate-severe pain. | As per codeine. |
Oxycodone | Comes in freebase, hydrochloride and terephthalate salt forms; freely soluble in water and practically insoluble in organic solvents; degrades upon contact with air. | Opioid receptor agonist. | PO. | Bioavailability = 60–87%; protein binding = 45%; volume of distribution = 2.6 L/kg; extensively metabolised in the liver via CYP3A4 and to a lesser extent via CYP2D6 to oxymorphone; half-life = 2–4 hours; excretion = urine (83%).[101] | Moderate-severe pain. | As per codeine. |
Oxymorphone | Comes in hydrochloride salt form; fairly soluble in water (1 in 4), practically insoluble in most organic solvents; degrades upon contact with air, light and temperatures outside 15 °C to 30 °C. | As per morphine. | PO, IM, SC. | Bioavailability = 10% (oral); protein binding = 10–12%; volume of distribution = 1.94–4.22 L/kg; hepatic metabolism; half-life = 7–9 hours, 9–11 hours (XR); excretion = urine, faeces.[102] | Postoperative analgesia/anaesthesia; moderate-severe pain. | As per codeine. |
Morphinans |
Butorphanol | Comes in tartrate salt form; sparingly soluble in water, insoluble in most organic solvents; degrades upon contact with air and at temperatures outside the range of 15 °C and 30 °C. | Kappa opioid receptor agonist; mu opioid receptor partial agonist. | IM, IV, intranasal. | Bioavailability = 60–70% (intranasal); protein binding = 80%; volume of distribution = 487 L; hepatic metabolism, mostly via hydroxylation; excretion = urine (mostly); half-life = 4.6 hours.[103] | Moderate-severe pain, including labour pain. | As above, but with a higher propensity for causing hallucinations and delusions. Respiratory depression is subject to ceiling effect. |
Levorphanol | Comes in tartrate salt form; fairly insoluble in water (1 in 50) and fairly insoluble in ethanol, chloroform and ether; unstable outside of 15 °C and 30 °C; phenanthrene derivative. | Mu opioid; NMDA antagonist; SNRI.[104] | PO, IM, IV, SC. | Protein binding = 40%; extensive first-pass metabolism; half-life = 12–16 hours, 30 hours (repeated dosing).[104][105] | Acute/chronic pain. | As per codeine. |
Nalbuphine | Comes primarily as its hydrochloride salt. | Full agonist at kappa opioid receptors, partial agonist/antagonist at the mu opioid receptors.[44] | IM, IV, SC. | Protein binding = not significant; hepatic metabolism; half-life = 5 hours; excretion = urine, faeces.[106][107] | Pain; anaesthesia supplement; opioid-induced pruritus. | As per codeine. Respiratory depression is subject to ceiling effect. |
Benzomorphans |
Dezocine | No data available. | Mixed opioid agonist-antagonist. | IM, IV. | Volume of distribution = 9–12 L/kg; half-life = 2.2–2.7 hours. | Moderate-severe pain. | As per codeine. |
Eptazocine | Comes as hydrobromide salt. | As per morphine. | IM, SC. | No data. | Moderate-severe pain. | As per codeine. |
Pentazocine | Comes in free, hydrochloride and lactate salt forms; fairly insoluble in water (1:30 or less), more soluble in ethanol and chloroform; degrades upon contact with air and light. | Kappa opioid receptor agonist; mu opioid receptor antagonist/partial agonist. | IM, IV, SC. | Bioavailability = 60–70%; protein binding = 60%; hepatic metabolism; half-life = 2–3 hours; excretion = urine (primary), faeces.[108][109] | Moderate-severe pain. | As per codeine. Respiratory effects are subject to a ceiling effect. |
Phenylpiperidines |
Anileridine | Comes in free, hydrochloride and phosphate forms; fairly insoluble in water, soluble in ethanol, ether and chloroform; degrades upon contact with air and light. | Mu opioid receptor agonist. | IM, IV. | No data. | Moderate-severe pain. | As per codeine. |
Ketobemidone | Comes in hydrochloride salt form; freely soluble in water, soluble in ethanol and fairly insoluble in dichloromethane. | Mu opioid; NMDA antagonist. | PO, IM, IV, rectal. | Bioavailability = 34% (oral), 44% (rectal); half-life = 2–3.5 hours.[110] | Moderate-severe pain. | As per other opioids. |
Pethidine | Comes in hydrochloride form; very soluble in water, sparingly soluble in ether, soluble in ethanol; degrades upon contact with air and light. | Mu opioid receptor agonist with some serotonergic effects. | IM, IV, PO, SC. | Bioavailability = 50–60%; protein binding = 65–75%; hepatic metabolism; half-life = 2.5–4 hours; excretion = urine (primarily).[111][112][113][114][115] | Moderate-severe pain. | As per other opioids; and seizures, anxiety, mood changes and serotonin syndrome. |
Open-chain opioids |
Dextromoramide | Comes in tartrate salt and free forms; soluble in water (tartrate salt). | Mu opioid. | IM, IV, PO, rectal. | No data available. | Severe pain. | As per other opioids. |
Dextropropoxyphene | Comes in free form, hydrochloride and napsilate salt forms; very soluble in water (HCl), practically insoluble in water (napsilate); degrades upon contact with light and air. | Mu opioid. | PO. | Protein binding = 80%; hepatic metabolism; half-life = 6–12 hours, 30–36 hours (active metabolite). | Mild-moderate pain. | As per other opioids, plus ECG changes. |
Dipipanone | Comes in hydrochloride salt form; practically insoluble in water and ether, soluble in acetone and ethanol. | Mu opioid. | PO, often in combination with cyclizine. | Half-life = 20 hours.[116] | Moderate-severe pain. | Less sedating than morphine, otherwise as per morphine. |
Levacetylmethadol† | Comes in hydrochloride salt form. | As above plus nicotinic acetylcholine receptor antagonist. | PO. | Protein binding = 80%; half-life = 2.6 days. | Opioid dependence. | As per other opioids, plus ventricular rhythm disorders. |
Levomethadone | Comes in hydrochloride salt form; soluble in water and alcohol; degrades upon contact with light. | Mu opioid; NMDA antagonist. | PO. | No data. | As per methadone. | As per methadone. |
Meptazinol | Comes in hydrochloride salt form; soluble in water, ethanol and methanol, fairly insoluble in acetone; unstable at temperatures greater than 25 °C. | Mixed opioid agonist-antagonist, partial agonist at mu-1 receptor; cholinergic actions exist. | IM, IV, PO. | Bioavailability = 8.69% (oral); protein binding = 27.1%; half-life = 2 hours; excretion = urine.[117] | Moderate-severe pain; perioperative analgesia; renal colic. | As per pentazocine. |
Methadone | Comes in hydrochloride salt form; soluble in water and ethanol; degrades upon contact with air and light and outside the temperature range of 15 °C and 30 °C. | Mu opioid; NMDA antagonist. | IM, IV, PO, SC. | Bioavailability = 36–100% (mean: 70–80%); protein binding = 81–97% (mean: 87%); volume of distribution = 1.9-8 L/kg (mean: 4 L/kg); hepatic metabolism, mostly via CYP3A4, CYP2B6 and to a lesser extent: CYP2C9, CYP2C19, CYP2D6 & CYP2C8; half-life = 5–130 hours (mean: 20–35 hours); excretion = urine (20–50%), faeces.[118] | Opioid addiction; chronic pain. | As per other opioids, plus QT interval prolongation. |
Piritramide | Comes in free or tartrate salt forms. | Mu opioid. | IM, IV, SC. | No data available. | Severe pain. | As per other opioids. |
Tapentadol | Comes in free and hydrochloride salt forms. | Mu opioid and norepinephrine reuptake inhibitor. | PO. | Bioavailability = 32%; protein binding = 20%; hepatic metabolism, mostly via CYP2C9, CYP2C19, CYP2D6; excretion = urine (70%), faeces; half-life = 4 hours. | Moderate-severe pain. | As per other opioids; less likely to cause nausea, vomiting and constipation. |
Tilidine | Comes in hydrochloride salt form; soluble in water, ethanol and dichloromethane; degrades upon contact with light. | Mu opioid metabolite, nortilidine. | PO. | No data. | Moderate-severe pain. | As per other opioids. |
Tramadol | Comes in hydrochloride salt form; freely soluble in water and methanol, insoluble in acetone; degrades at temperatures less than 15 °C and 30 °C and upon contact with light. | Mu opioid (mostly via its active metabolite, O-desmethyltramadol) and SNRI. | IM, IV, PO, rectal. | Bioavailability = 70–75% (oral), 100% (IM); protein binding = 20%; hepatic metabolism, via CYP3A4 and CYP2D6; half-life = 6 hours; excretion = urine, faeces. | Moderate-severe pain. | As per other opioids but with less respiratory depression and constipation. Psychiatric AEs reported. Serotonin syndrome possible if used in conjunction with other serotonergics. |
Anilidopiperidines |
Alfentanil | Comes in hydrochloride salt form; freely soluble in ethanol, water, methanol; degrades upon contact with air and light. | Mu opioid. | Epidural, IM, IV, intrathecally. | Protein binding = 90%; volume of distribution = small; half-life = 1–2 hours; hepatic metabolism, mostly via CYP3A4; excretion = urine. | Procedural anaesthesia. | As per other opioids. Very sedating. |
Fentanyl | Comes in free, hydrochloride salt, citrate salt forms; practically insoluble in water (free form), soluble in water (citrate salt form), freely soluble in ethanol and methanol; degrades outside the temperature range of 15 °C and 30 °C and upon contact with light. | Mu opioid. | Buccal, epidermal, IM, IV, intrathecal, intranasal, SC, sublingual. | Bioavailability = 50% (buccal), 89% (intranasal); protein binding = 80%; hepatic metabolism, mostly via CYP3A4; half-life = 219 min; excretion = urine (primary), faeces. | Moderate-severe pain (including labour pain); adjunct to anaesthesia. | As with other opioids, with less nausea, vomiting, constipation and itching and more sedation. |
Remifentanil | Comes in hydrochloride salt. | Mu opioid. | IV. | Protein binding = 70%; hydrolysed by blood and tissue esterases; half-life = 20 min; excretion = urine (95%). | Anaesthesia maintenance. | As with fentanyl. |
Sufentanil | Comes in free and citrate salt forms; soluble in water, ethanol and methanol; degrades upon contact with light and temperatures outside 15 °C and 30 °C. | Mu opioid. | Epidural, IV, intrathecal, transdermal. | Protein binding = 90%; half-life = 2.5 hours; excretion = urine (80%). | Adjunct to anaesthesia and moderate-severe pain. | As with fentanyl. |
Other analgesics |
Acetanilide | No data. | Paracetamol prodrug. | PO. | No data. | Pain; fever. | Cancer; AEs of paracetamol. |
Amitriptyline | Comes in free form and in hydrochloride and embonate salt forms; practically insoluble in water (embonate salt), freely soluble in water (HCl); degrades upon contact with light. | SNRI. | PO. | Hepatic metabolism, via CYP2C19, CYP3A4; active metabolite, nortriptyline; half-life = 9–27 hours; excretion = urine (18%), faeces. | Neuropathic pain; nocturnal enuresis; major depression; migraine prophylaxis; urinary urge incontinence. | Sedation, anticholinergic effects, weight gain, orthostatic hypotension, sinus tachycardia, sexual dysfunction, tremor, dizziness, sweating, agitation, insomnia, anxiety, confusion. |
Dronabinol | Comes in free form; degrades upon contact with light. | Cannabinoid receptor partial agonist. | PO. | Bioavailability = 10–20%; protein binding = 90–99%; volume of distribution = 10 L/kg; hepatic metabolism; half-life = 25–36 hours, 44–59 hours (metabolites); excretion = faeces (50%), urine (15%).[119] | Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain. | Dizziness, euphoria, paranoia, somnolence, abnormal thinking, abdominal pain, nausea, vomiting, depression, hallucinations, hypotension, special difficulties, emotional lability, tremors, flushing, etc. |
Duloxetine | Comes in hydrochloride salt form; slightly soluble in water, freely soluble in methanol; degrades upon contact with light. | SNRI. | PO. | Protein binding > 90%; volume of distribution = 3.4 L/kg; hepatic metabolism, via CYP2D6, CYP1A2; half-life = 12 hours; excretion = urine (70%), faeces (20%).[120] | Major depression; generalised anxiety disorder; neuropathic pain. | Anticholinergic effects, GI effects, yawning, sweating, dizziness, weakness, sexual dysfunction, somnolence, insomnia, headache, tremor, decreased appetite. |
Flupirtine | Comes as maleate salt. Chemically related to retigabine. | Potassium channel (Kv7) opener.[121] | PO, rectal. | Bioavailability = 90% (oral), 72.5% (rectal); protein binding = 80%; volume of distribution = 154 L; hepatic metabolism; half-life = 6.5 hours; excretion = urine (72%). | Pain; fibromyalgia; Creutzfeldt–Jakob disease. | Drowsiness, dizziness, heartburn, dry mouth, fatigue and nausea.[122] |
Gabapentin | Comes in free and enacarbil salt forms; fairly insoluble in ethanol, dichoromethane, fairly soluble in water. | Binds to the α2δ-1 subunit of voltage gated calcium ion channels in the spinal cord. May also modulate NMDA receptors and protein kinase C. | PO. | Half-life = 5–7 hours. | Neuropathic pain; epilepsy. | Fatigue, sedation, dizziness, ataxia, tremor, diplopia, nystagmus, amblyopia, amnesia, abnormal thinking, hypertension, vasodilation, peripheral oedema, dry mouth, weight gain and rash. |
Milnacipran | No data. | SNRI. | PO. | Bioavailability = 85–90%; protein binding = 13%: volume of distribution = 400 L; hepatic metabolism; half-life = 6–8 hours (L-isomer), 8–10 hours (D-isomer); excretion = urine (55%).[123] | Fibromyalgia. | As per duloxetine, plus hypertension. |
Nabiximols | Contains cannabidiol and dronabinol in roughly equal concentrations. | As per dronabinol. | Buccal spray. | Not available. | Neuropathic pain and spasticity as part of MS. | As per dronabinol. |
Nefopam | Comes in a hydrochloride salt form. Chemically related to orphenadrine. | Unknown; serotonin-norepinephrine-dopamine reuptake inhibitor. | PO, IM. | Protein binding = 73%; half-life = 4 hours; excretion = urine, faeces (8%). | Analgesia, especially postoperative; hiccups. | Has antimuscarinic and sympathomimetic effects.[124] |
Paracetamol | Comes in free form; practically insoluble in water, freely soluble in ethanol; degrades upon contact with moisture, air and light. | Multiple; inhibits prostaglandin synthesis in the CNS, an active metabolite, AM404, is an anandamide reuptake inhibitor. | PO, IV, IM, rectal. | Protein binding = 10–25%; volume of distribution = 1 L/kg; hepatic metabolism; half-life = 1–3 hours; excretion = urine.[125] | Analgesia and fever reduction. | Hepatotoxicity; hypersensitivity reactions (rare), including Stevens–Johnson syndrome; hypotension (rare; IV). |
Phenacetin | No data. | Prodrug to paracetamol. | PO. | No data. | Analgesia and fever reduction. | Haematologic, nephrotoxicity, cancer and paracetamol AEs. |
Pregabalin | Comes in free form. | As per gabapentin. | PO. | Bioavailability = 90%; half-life = 6.3 hours; hepatic metabolism; excretion = urine (90%).[126] | Neuropathic pain; anxiety; epilepsy. | As per gabapentin. |
Propacetamol | Freely soluble in water; degrades upon contact with moisture. | Prodrug to paracetamol. | IM, IV. | No data available. | Analgesia and fever reduction. | As per paracetamol. |
Ziconotide | Peptide. | N-type calcium-channel blocker. | Intrathecal. | Protein binding = 50%; half-life = 2.9–6.5 hours; excretion = urine (<1%).[127] | Chronic pain. | CNS toxicity (abnormal gait, abnormal vision, memory problems, etc.); GI effects.[127] |
Where † indicates products that are no longer marketed. |